ClinicalTrials.gg
CompletedNCT03497949Updated May 1, 2026

Peri-operative Vasopressor Support in Patients Operated for an Acute Hip Fracture (AHF)

An observational study in Hip Fractures and Intraoperative Hypotension, sponsored by Sahlgrenska University Hospital. Completed at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Sahlgrenska University Hospital · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
997
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Hip Fractures by Sahlgrenska University Hospital — none open to participants now, none under way, none of them phase 3. Hip Fractures · Sahlgrenska University Hospital.

Started
2017
the only one that year
Observational
5 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Hip Fractures by Sahlgrenska University Hospital, this one is the only one that started in 2017, is one of 5 observational ones, and was the 5th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

None of the 10 studies in Hip Fractures by Sahlgrenska University Hospital is open now. The open studies under Hip Fractures, anywhere →

Where they have run

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Hip Fractures by Sahlgrenska University Hospital as a file.
02

Study summary

The incidence of hypotension perioperatively during operation of an acute hip fracture is unknown. As a surrogate factor the usage of vasopressor support is more adequate as the registration of vasopressor drugs are many times not complete in records. The investigators retrospectively investigated the anesthetic journals of 1100 patients with an acute hip fracture (AHF) noting confounding factors and the usage of vasopressors either by injections or infusions and then correlated these results to mortality at 30-, 90- and 365- days

Read the detailed description

The incidence of hypotension perioperatively during operation of an acute hip fracture is unknown. As a surrogate factor the usage of vasopressor support is more adequate as the registration of vasopressor drugs are many times not complete in records. The investigators retrospectively investigated the anesthetic journals of 1100 patients with an acute hip fracture (AHF) noting confounding factors and the usage of vasopressors either by injections or infusions and then correlated these results to mortality at 30-, 90- and 365-days Confounding factors were; all comorbitity, age, ASA grade as well as type of anesthesia

03

Conditions studied

  • Hip Fractures
  • Intraoperative Hypotension

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Single center study of patients operated with an acute hip fracture

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with an acute hip fracture

Exclusion criteria

Exclusion Criteria

  • Only one fracture within time-limit.
  • Unretreivable mortality data
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
997 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Mortality

    Time frame: 365 days

07

Study locations

1 site
  • SahlgrenskaUH
    Mölndal, VGR 43180, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Mar 2018, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2018
First posted
Apr 13, 2018
StartActual
Jan 20, 2017
Primary completionActual
Mar 31, 2018
CompletionActual
Mar 31, 2018
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03497949
Responsible party
Bengt Nellgård (Clinical professor, Sahlgrenska University Hospital) — Principal investigator
First posted
Apr 13, 2018
Start date
Jan 20, 2017
Primary completion
Mar 31, 2018
Completion
Mar 31, 2018
Last update
May 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion